CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 0	$ 1,061,000
Costs and expenses:
Patient expenses	0	86,000
Selling, general and administrative	360,000	298,000
Total	360,000	384,000
Operating (loss) income	(360,000)	677,000
Total other (expense) income
Interest expense	0	(2,000)
Interest income - sales-type sublease	0	8,000
Loss from investments in unconsolidated entities, net	(133,000)	(139,000)
Total other expense	(133,000)	(133,000)
(Loss) income before income taxes	(493,000)	544,000
Provision for income taxes	2,000	252,000
Net (loss) income	(495,000)	292,000
Net loss attributable to noncontrolling interests	74,000	0
Net (loss) income attributable to U.S. Neurosurgical Holdings, Inc.	$ (421,000)	$ 292,000
Basic net (loss) income per share attributable to U.S. Neurosurgical Holdings, Inc. (in dollars per share)	$ (0.05)	$ 0.04
Diluted net (loss) income per share attributable to U.S. NeuroSurgical Holdings, Inc. (in dollars per share)	$ (0.05)	$ 0.04
Weighted average common shares outstanding, basic (in shares)	7,792,185	7,792,185
Weighted average common shares outstanding, diluted (in shares)	7,792,185	7,792,185